IntegriChain

The solutions created by IntegriChain's 700 employees enable laboratories to facilitate the distribution of medical products.

Indeed, the introduction of a drug on the American market generally sees it pass through a large number of intermediaries, increasing distribution costs and reducing margins.

To make it easier for laboratories to distribute their products and avoid excessive price hikes for patients, IntegriChain offers software solutions, consulting services and data analysis, which on average reduce the revenue shortfall of its 400 major customers by 7%.

This innovative positioning makes IntegriChain a pioneer in a booming sector that is experiencing significant growth: recently valued at $265 million, the company has also forecast a gross margin on EBITDA of 22% in 2023. Over 90% of its revenues are recurrent, thanks to a high level of customer engagement.

As a solid, well-established company in an increasingly important market, IntegriChain is keen to continue asserting its position as software leader for the pharmaceutical industry.